Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Medidata Launches Rave Companion, the First Scalable Solution for Automating EHR Data Entry into Rave EDC

Rave Companion Modernizes the EDC User Experience, Saving Thousands of Potential Errors for Clinical Trial Sites and Data Managers 

Medidata, a Dassault Systèmes company, announced plans to launch Rave Companion, an innovative, scalable, patent pending technology helping clinical trial sites save time and reduce errors in transferring EHR (electronic health record) data to the Rave EDC (electronic data capture) system. Rave Companion addresses the long-standing industry challenge of duplicate data entry by enabling structured and unstructured data from any electronic health record to be directly utilized by Rave EDC, within a few clicks.

Latest NaturalAI Insights: InspireXT Announces Acquisition Of NaturalAI – A Conversational Artificial Intelligence Platform To Expand Its Solution Portfolio

“The number of data points collected as part of a clinical trial has increased exponentially and sites are looking for scalable and easy to use solutions to connect to their EHR and reduce data entry,” said Dan Braga, vice president EHR Solutions and Healthcare at Medidata. “Rave Companion is an elegant solution that helps sites utilize existing data from any EHR system instead of re-entering it for clinical trials purposes.”

Medidata has conducted more than 29,000 trials, with more than 1.5M life science professionals around the world using its industry-leading platform. Rave Companion was designed in a way to provide out of the box functionality for unstructured data, as well as advanced EHR integration capabilities for those sites connected to Medidata’s broad and quickly expanding network of research sites. Rave Companion works by mirroring the Rave eCRF schema in a “companion” tool that floats on top of the screen and follows site users as they navigate through various records systems that are needed to contribute to the research database.

For unstructured data, or for sites not yet connected to Medidata’s network, Rave Companion eliminates “swivel chair” activities and allows the Rave EDC experience to travel with users as they go to their EHR, or other clinical systems, to find the appropriate patient data. Instead of coming back to type it in, users can now simply click on the value and the eCRF will be filled out for them.

Related Posts
1 of 33,438

AI News: Infobip Creates AI-powered Chatbot for Uber

Coming next year, Rave Companion will also include the presentation of EHR data directly within the solution, meaning that users will never have to leave Rave EDC to complete eCRFs, keeping the whole experience in one place.

Medidata will unveil Rave Companion at its premier life sciences event, NEXT New York November 15-16. Participants will learn how Medidata is addressing the challenges of data entry during a session titled, “Solving the EHR to EDC Challenge: A New Perspective, Approach and Technology,” featuring Gene Vinson, executive director, Clinical Vendor Management at Syneos Health and Medidata’s Dan Braga and Samir Jain, senior director, EHR Solutions.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

Latest Aithority Insights : NVIDIA Raises the Standard of Low Code DevOps with the NVIDIA AI Enterprise 2.1

 [To share your insights with us, please write to] 

Comments are closed.